Axsome Therapeutics (AXSM) hissesi, piyasadaki genel düşüşe rağmen %18,96 oranında yükselerek dikkat çekti. Bu yükseliş, Needham'ın AXSM için 'Al' tavsiyesini sürdürmesi ve fiyat hedefini artırmasıyla desteklendi. SPY, QQQ ve DIA gibi ETF'lerde ise hafif düşüşler yaşandı.
AXSM Hissesi %18,96 Yükselerek 177,00$'a Ulaştı, ETF'lerde Hafif Düşüşler Görüldü
AXSM hissesi %18,96 yükseldi ve 177$'a ulaştı. ETF'lerdeki düşüşe rağmen AXSM dikkat çekti. Needham'ın 'Al' tavsiyesi etkili oldu. Detaylar burada.
Sıkça Sorulan Sorular
Why did Axsome Therapeutics (AXSM) stock surge today?
AXSM stock surged nearly 19% after Needham maintained a 'Buy' rating and raised its price target for Axsome Therapeutics. This positive analyst action drove significant investor interest, making it an outlier in a declining market.
What was AXSM's closing price and percentage gain?
Axsome Therapeutics (AXSM) closed at $177.00, marking an impressive gain of +18.96%. This strong performance contrasted sharply with minor pullbacks seen in broader market ETFs like SPY, QQQ, and DIA.
How did the broader market perform compared to AXSM?
While AXSM surged, benchmark ETFs SPY, QQQ, and DIA experienced minor pullbacks, closing down by -0.12%, -0.23%, and -0.21% respectively. AXSM's rally was driven by company-specific news, defying the general market trend.